Target intelligence / Profile preview

Pyruvate dehydrogenase phosphatase catalytic subunit 1 (PDP1)

Target
PDP1
Molecular classification
Enzyme, Protein serine/threonine phosphatase, Protein phosphatase 2C (PP2C) family
01

Overview

Pyruvate dehydrogenase phosphatase catalytic subunit 1 (PDP1) is a mitochondrial enzyme of the protein phosphatase 2C family that catalyzes the Mg2+/Mn2+-dependent dephosphorylation and activation of the E1 subunit of the pyruvate dehydrogenase complex (PDC). This reactivates the complex, facilitating the conversion of pyruvate to acetyl-CoA—a critical link between glycolysis and the tricarboxylic acid cycle, essential for cellular energy production. PDP1 activity is regulated by calcium and is predominantly expressed in skeletal muscle, with mutations leading to rare, autosomal recessive disorders characterized by lactic acidosis, developmental delay, and neurological symptoms. PDP1 is a validated enzyme target, but no selective pharmacological modulators are yet in approved therapeutic use[1][2][3][7].

Other names
Pyruvate dehydrogenase [acetyl-transferring]-phosphatase 1, mitochondrialPDPPPM2CPPM2APDHPDPCProtein phosphatase 2C, magnesium-dependent, catalytic subunitProtein phosphatase, Mg2+/Mn2+ dependent 2APyruvate dehydrogenase (Lipoamide) phosphatase-phosphatase
02

Mechanism of action

Enhancement or inhibition of PDP1 would regulate the dephosphorylation and activation status of the pyruvate dehydrogenase complex, modulating cellular acetyl-CoA production and mitochondrial energy output[2][3][7]

03

Biological functions

Regulation of pyruvate metabolismActivation of pyruvate dehydrogenase complexCatalysis of dephosphorylation in mitochondrial matrixEnergy production
04

Disease associations

Pyruvate dehydrogenase phosphatase deficiencyPrimary lactic acidosisNeurological disorders due to impaired energy metabolism
05

Safety considerations

Impairment of PDP1 activity can cause severe lactic acidosis and profound neurological dysfunction in humans[3]Manipulation could lead to catastrophic defect in energy metabolism if not tightly regulated
06

Interacting drugs

None established or clinically approved as of 2024; certain metabolic modulators may indirectly affect this pathway but no direct PDP1-targeting drugs are currently used in clinical practice[2][3][7]
07

Biomarkers

Mutation or loss of function in PDP1 serves as a biomarker for certain forms of pyruvate dehydrogenase complex deficiency and mitochondrial disorders[3]

Beyond the preview

Go deeper on Pyruvate dehydrogenase phosphatase catalytic subunit 1 (PDP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pyruvate dehydrogenase phosphatase catalytic subunit 1 (PDP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call